STYLAGE® S BI-FLEX® with Lidocaine

STYLAGE® S BI-FLEX® with Lidocaine — Injectable HA Dermal Filler for Superficial Wrinkles & Fine Line Correction

Product Specifications

• Drug Class: Injectable hyaluronic acid dermal filler (cross-linked, superficial plane, IPN-Like Technology™, with mannitol and lidocaine)
• Active Ingredients: Hyaluronic acid (cross-linked) 16mg/g; Mannitol 9mg/mL; Lidocaine 3mg/mL
• Manufacturer: Laboratories VIVACY
• Brand: STYLAGE®
• Country of Origin: France
• Strength: 16mg/g HA; 9mg/mL Mannitol; 3mg/mL lidocaine
• Dosage Form: Injectable gel — 2 × 0.8mL prefilled BI-FLEX® syringes + 4 × 30G ½ needles
• FDA Status: Not currently approved by the US FDA
• Regulatory Status: CE-marked (EU); current as of 2026

STYLAGE® S BI-FLEX® with Lidocaine Injection: Mechanism of Action

STYLAGE® S BI-FLEX® with Lidocaine works by integrating cross-linked hyaluronic acid into the superficial dermis, where the gel binds water and restores hydration within the treatment area. This process delivers immediate smoothing of superficial wrinkles and fine lines while supporting skin texture refinement in areas affected by photoaging and early volume loss.

A defining feature of the Stylage dermal filler range is IPN-Like Technology™, which creates two interpenetrating HA polymer networks. Compared with conventional single-network injectable dermal fillers, this structure improves cohesivity, elasticity, and resistance to mechanical deformation, helping maintain stability in dynamic facial areas while preserving natural movement.

Mannitol at 9mg/mL functions as a free radical scavenger, helping reduce oxidative degradation of hyaluronic acid after injection. This stabilization is relevant when practitioners are asked how long STYLAGE® filler lasts, as longevity is influenced by factors such as skin type, treatment area, lifestyle, and sun exposure.

Lidocaine at 3mg/mL is integrated into the gel to improve comfort during lidocaine administration and superficial placement. The BI-FLEX® syringe system, previously known as Bi-SOFT®, was redesigned for improved ergonomics and injection precision during superficial-plane treatment. Like other HA fillers, the gel gradually degrades through endogenous hyaluronidase activity and may be reversed if clinically required.

About STYLAGE® S BI-FLEX® with Lidocaine

Manufactured by Laboratories VIVACY in France, STYLAGE® S BI-FLEX® with Lidocaine belongs to a CE-marked family of Stylage filler products developed for facial rejuvenation and wrinkle correction. With a lower HA concentration than STYLAGE® M or L, this formulation is optimized for superficial dermal use rather than volumization.

Practitioners evaluating whether STYLAGE® is a good filler for superficial indications will find the answer in its formulation choices: IPN-Like Technology™, mannitol-enhanced durability, and the precision-focused BI-FLEX® syringe system. These features support controlled superficial delivery and a tolerability profile consistent with established HA fillers used in aesthetic medicine.

The BI-FLEX® presentation represents the evolution of the earlier Bi-SOFT® syringe platform. While the core gel remains unchanged, the updated syringe design was introduced to improve ergonomics, injection precision, and practitioner handling. This distinction is worth noting for clinics re-ordering or comparing presentations.

Clinics seeking to buy STYLAGE® S BI-FLEX® wholesale should contact Medica Depot’s support representatives for further information.

Indications & Clinical Use

STYLAGE® S BI-FLEX® with Lidocaine is a fine-density injectable dermal filler designed specifically for delicate and precise corrections. Unlike more robust formulations within the VIVACY range, its rheological profile is uniquely calibrated for placement in the superficial dermis. Because it lacks the high lifting capacity or structural density required for broad tissue expansion, it is not indicated for deep wrinkle correction or mid-face volumization.

The product is clinically indicated for the following aesthetic applications:

• Fine Line & Superficial Wrinkle Treatment: Precise correction of superficial dermal creases, including periorbital lines (crow’s feet), perioral lines (smoker’s lines), and minor, shallow forehead furrows.
• Layered Correction Protocols: Addressing the superficial cutaneous component of deeper creases—such as nasolabial folds or marionette lines—when used sequentially over a deeper-plane structural filler (such as STYLAGE® M or L).
• Textural Refinement: Smoothing out superficial skin texture irregularities where a highly fluid, low-viscosity hyaluronic acid matrix is required for seamless tissue integration.

Patient Selection and Clinical Guidelines

Practitioners should carefully analyze the following patient parameters:

• Skin Quality: Native thickness and overall condition of the cutaneous tissue.
• Aging Status: Degree of photoaging and loss of superficial elasticity.
• Micro-anatomy: Local tissue dynamics and muscle movement in the target zone.
• Clinical History: Patient skin type and previous superficial injectable treatments.

Safety Requirement

STYLAGE® S BI-FLEX® with Lidocaine must exclusively be administered by licensed aesthetic medicine professionals who are thoroughly trained in facial anatomy and precise, superficial injection techniques.

Administration, Side Effects & Safety

Administration is performed through intradermal injection into the superficial dermis using the supplied 30G ½ needles and BI-FLEX® syringe system. Common techniques include serial puncture and superficial linear threading, depending on practitioner preference and the treatment area.

Because lidocaine is integrated into the gel at 3mg/mL, patient discomfort during injection may be reduced, although topical anesthetic use remains optional. Standard precautions include careful aseptic technique, slow injection, and avoidance of intravascular placement.

The most common side effects include:

• Transient redness
• Swelling
• Tenderness
• Bruising at the injection site

These reactions typically resolve within a few days without intervention. Patients are generally advised to avoid excessive sun exposure, intense heat, and strenuous exercise until erythema and edema have subsided.

Although uncommon, serious adverse events associated with injectable dermal fillers may include vascular occlusion, skin necrosis, and visual disturbance. Practitioners should screen patients for hypersensitivity to hyaluronic acid or amide-type anesthetics before treatment.

Legal & Regulatory Status

STYLAGE® S BI-FLEX® with Lidocaine is manufactured in France by Laboratories VIVACY and is CE-marked for professional aesthetic use within the European Union and other approved markets. As of 2026, STYLAGE® fillers have not received FDA approval for cosmetic use in the United States. Distribution and use are restricted to licensed medical professionals and registered aesthetic clinics. Practitioners should verify local regulatory requirements, import policies, and product authenticity before ordering. Information on this page is current as of 2026 and is subject to change.

Practitioners wishing to buy STYLAGE® or buy dermal fillers through an authorized channel should confirm product authenticity and documentation with their chosen distributor. For sourcing guidance and information, contact Medica Depot’s support representatives.

Citations

1. Sundaram H, Liew S, Signorini M, et al. Global aesthetics consensus: hyaluronic acid fillers and botulinum toxin type A — recommendations for combined treatment and optimizing outcomes in diverse patient populations. Plast Reconstr Surg. 2016;137(5):1410-1423. doi: 10.1097/prs.0000000000002119
2. DeLorenzi C. Complications of injectable fillers, part 2: vascular complications. Aesthet Surg J. 2014;34(4):584-600. doi: 10.1177/1090820×14525035
3. International Society of Aesthetic Plastic Surgery. Patient safety guidance library. ISAPS. https://www.isaps.org/education/publications/patient-safety-guidance-library/

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.